Tolerability and Safety of Switching from Rituximab to Ocrelizumab: Evaluating Factors Associated with Infusion Related Reactions

BACKGROUND: Ocrelizumab and rituximab are frequently used treatments for multiple sclerosis (MS). Data on switching from rituximab to ocrelizumab is limited. OBJECTIVES: To assess the frequency, severity, and factors of infusion related reactions (IRRs) in patients with MS who switch from rituximab...

Descripción completa

Detalles Bibliográficos
Autores principales: Alvarez, Enrique, Nair, Kavita V., Sillau, Stefan, Shelton, Ian, Seale, Rebecca, Selva, Sean, Corboy, John, Vollmer, Timothy L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743958/
https://www.ncbi.nlm.nih.gov/pubmed/35024160
http://dx.doi.org/10.1177/20552173211069359

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8743958/
https://www.ncbi.nlm.nih.gov/pubmed/35024160
http://dx.doi.org/10.1177/20552173211069359

Ejemplares similares